Date Title Description PDF
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download

Pages

Date Title Description PDF
13 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 October and 12 October 2023 Download
06 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 September and 5 October 2023 Download
02 Oct 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2023 Download
29 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 September and 28 September 2023 Download
22 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 September and 21 September 2023 Download

Pages

Date Title Description PDF
05 Jul 2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. Download
02 Jul 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019 Download
26 Jun 2019 Información sobre dividendos The Company informs about the dividends payment Download
12 Jun 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting Download
08 May 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting Download

Pages